Singlomics Announces First Patient Dosed in Phase I Clinical Trial of DXP-106 (IL-1RAP mAb) in China

B BEIJING, April 7, 2026 /PRNewswire/ — Singlomics Biopharmaceuticals, an innovative clinical-stage biopharmaceutical company focused on the discovery and development of antibody therapeutics for oncology,…
posteditor
posteditor
Articles: 16137

Other News